Validation of a De Novo Health Economic Model for Finerenone in Heart Failure with Left Ventricular Ejection Fraction ≥40. [PDF]
Lemański T +5 more
europepmc +1 more source
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source
Left ventricular ejection fraction and myocardial fibrosis in sudden cardiac death. [PDF]
Silvola H +8 more
europepmc +1 more source
Assessment of HeartModel® automated left ventricular ejection fraction for patients with hypertrophic cardiomyopathy. [PDF]
Morrissey J +9 more
europepmc +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Enhanced prediction of left ventricular ejection fraction using electrocardiography with the addition of clinical metadata. [PDF]
Park HW, Kang T, Seo YH, Park JH.
europepmc +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Minimally invasive cardiac surgery - coronary artery bypass grafting in patients with low left ventricular ejection fraction. [PDF]
Luo ZR +5 more
europepmc +1 more source
Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction. [PDF]
Johansson JSM +5 more
europepmc +1 more source
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source

